SELLAS Life Sciences Group Inc. (NASDAQ: SLS) dropped 15.07% after the company released initial immunobiological and clinical data from the phase1/2 clinical study with its flagship candidate galinpepimut-S (GPS) in combination with pembrolizumab. GPS is the SELLAS’ Wilms Tumor-1 targeting peptide treatment.  The study conducted in collaboration with Merck The […]